Intellia Therapeutics saw a boost after Wedbush analyst raised its price target to $13, signaling potential upside from its current $12.64 share price. The FDA granted Priority Review to Intellia's lonvo-z treatment for Hereditary Angioedema, with a decision expected by March 10, 2027. The company also secured a $400 million non-dilutive loan to support the potential U.S. launch of lonvo-z, underscoring confidence in its gene-editing technology and growth prospects in precision medicine.
Polkadot (DOT) traded around $1.24, slightly down by 0.56% over 24 hours, staying within a recent range of $1.19 to $1.30. The token's price is testing resistance near $1.27, with technical indicators showing flat momentum and no clear directional sh...
A Hyperliquid address reduced its short position in Ether from 19,762.81 ETH (about $51.28 million) on October 7 to 10,032.42 ETH (about $25.09 million) by October 11. Ether was priced around $2,500 when the latest position was reported. This reducti...
Starknet (STRK) led the top 90 cryptocurrencies by market cap with a 52.54% gain in 24 hours, trading at $0.109. This surge extended its previous 45.02% rise. Other notable gainers included Aerodrome Finance (AERO) up 13.79% and Injective (INJ) up 7....
Worldcoin (WLD) surged 7.4% in the last 24 hours, outperforming many top cryptocurrencies despite a recent market correction that caused significant long liquidations. The price rebound led to some short liquidations, signaling renewed buying interes...
STRK, a layer-2 blockchain scaling solution, surged 53.3% in 24 hours to $0.1090, reflecting growing market interest in projects that improve blockchain efficiency. This sharp rise comes despite a slight overall market dip and steady Bitcoin dominanc...
